|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,408.40 INR | +0.49% |
|
-0.65% | -36.29% |
| Nov. 17 | Jefferies Adjusts Concord Biotech's Price Target to INR1,500 From INR1,600, Keeps at Hold | MT |
| Nov. 14 | Concord Biotech Limited, Q2 2026 Earnings Call, Nov 14, 2025 |
| Capitalization | 147B 1.64B 1.41B 1.32B 1.23B 2.27B 2.47B 15.42B 5.95B 69.59B 6.14B 6.01B 254B | P/E ratio 2026 * |
37.9x | P/E ratio 2027 * | 29.1x |
|---|---|---|---|---|---|
| Enterprise value | 144B 1.59B 1.37B 1.28B 1.2B 2.21B 2.4B 15.02B 5.8B 67.78B 5.98B 5.86B 248B | EV / Sales 2026 * |
10.9x | EV / Sales 2027 * | 8.6x |
| Free-Float |
24.94% | Yield 2026 * |
0.79% | Yield 2027 * | 1% |
Last Transcript: Concord Biotech Limited
| 1 day | +0.49% | ||
| 1 week | -0.65% | ||
| Current month | -0.65% | ||
| 1 month | -0.21% | ||
| 3 months | -15.04% | ||
| 6 months | -26.90% | ||
| Current year | -36.29% |
| 1 week | 1,392 |  | 1,445.1 |
| 1 month | 1,389.9 | | 1,513 |
| Current year | 1,345 | | 2,451.7 |
| 1 year | 1,345 | | 2,451.7 |
| 3 years | 900.05 | | 2,664 |
| 5 years | 900.05 | | 2,664 |
| 10 years | 900.05 | | 2,664 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 73 | 2000-05-09 | |
| Chief Executive Officer | - | 2011-08-31 | |
Lalit Sethi
DFI | Director of Finance/CFO | 59 | 2022-03-13 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | 2008-06-29 | |
| Chairman | 73 | 2000-05-09 | |
| Director/Board Member | 81 | 2017-01-30 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.49% | -0.65% | -35.15% | - | 1.64B | |
| -0.61% | -7.92% | -7.67% | -3.89% | 73.7B | |
| -0.81% | -1.18% | -34.44% | -38.79% | 58.94B | |
| +3.17% | +2.91% | +33.57% | +247.91% | 54.7B | |
| -2.32% | +64.10% | +64.10% | +64.10% | 51.57B | |
| -0.37% | -0.43% | +14.91% | -37.80% | 26.6B | |
| -1.66% | -2.23% | +143.39% | +224.51% | 20.25B | |
| +2.05% | -1.86% | +35.04% | +24.21% | 20.13B | |
| -12.04% | -14.35% | +49.18% | +1,058.63% | 16.58B | |
| -1.50% | +2.26% | +155.78% | +687.59% | 14.19B | |
| Average | -1.36% | -2.54% | +41.87% | +247.38% | 33.83B | |
| Weighted average by Cap. | -0.77% | -2.49% | +28.14% | +135.53% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 13.11B 146M 125M 117M 109M 202M 220M 1.37B 530M 6.19B 547M 535M 22.64B | 16.52B 184M 158M 148M 138M 254M 277M 1.73B 667M 7.8B 689M 674M 28.52B |
| Net income | 3.89B 43.23M 37.16M 34.82M 32.45M 59.94M 65.19M 407M 157M 1.84B 162M 159M 6.72B | 5.06B 56.26M 48.36M 45.3M 42.23M 78M 84.84M 530M 205M 2.39B 211M 207M 8.74B |
| Net Debt | -3.84B -42.62M -36.64M -34.32M -31.99M -59.09M -64.27M -401M -155M -1.81B -160M -157M -6.62B | -5.3B -58.92M -50.65M -47.45M -44.23M -81.69M -88.85M -555M -214M -2.5B -221M -216M -9.16B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-12-05 | 1,408.40 ₹ | +0.49% | 51,263 |
| 25-12-04 | 1,401.60 ₹ | -0.24% | 63,061 |
| 25-12-03 | 1,405.00 ₹ | -2.27% | 61,190 |
| 25-12-02 | 1,437.60 ₹ | +0.33% | 23,896 |
| 25-12-01 | 1,432.90 ₹ | +1.08% | 65,962 |
Delayed Quote NSE India S.E., December 05, 2025 at 06:49 am EST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CONCORDBIO Stock
Select your edition
All financial news and data tailored to specific country editions
